argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.
Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions.
The main ***** et involved is FB102, Forte Biosciences' first-in-class anti-CD122 antibody, which will be added to argenx's immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease.
These studies were a key factor in deciding to proceed from a strategic investment to acquisition by argenx.
Forte Biosciences expects to release Phase II data for FB102 in the second half of this year.
#forte #biosciences
Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions.
The main ***** et involved is FB102, Forte Biosciences' first-in-class anti-CD122 antibody, which will be added to argenx's immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease.
These studies were a key factor in deciding to proceed from a strategic investment to acquisition by argenx.
Forte Biosciences expects to release Phase II data for FB102 in the second half of this year.
#forte #biosciences
3 months ago
